Department of Gastroenterology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Front Immunol. 2023 Oct 4;14:1264912. doi: 10.3389/fimmu.2023.1264912. eCollection 2023.
Esophageal cancer is the sixth most common cancer worldwide. Approximately 50% of patients have locally advanced disease. The CROSS and NEOCRTEC5010 trials have demonstrated that neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for patients with resectable disease. However, a pathological complete response is frequently not achieved, and most patients have a poor prognosis. The CheckMate 577 trial demonstrates that nivolumab adjuvant therapy improves disease-free survival in patents without a pathological complete response. However, there are still numerous clinical questions of concern that remain controversial based on the results of the subgroup analysis. In this review, we aim to offer constructive suggestions addressing the clinical concerns raised in the CheckMate 577 trial.
食管癌是全球第六大常见癌症。大约 50%的患者患有局部晚期疾病。CROSS 和 NEOCRTEC5010 试验表明，新辅助放化疗后手术是可切除疾病患者的标准治疗方法。然而，病理完全缓解率通常较低，大多数患者预后不良。CheckMate 577 试验表明，纳武利尤单抗辅助治疗可改善无病理完全缓解患者的无病生存。然而，基于亚组分析结果，仍有许多临床关注问题存在争议。在这篇综述中，我们旨在针对 CheckMate 577 试验中提出的临床关注问题提供建设性建议。
